Astellas Pharma Inc. and Cullgen Inc. announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders.
POXEL SA announced its participation at the ULF Scientific Symposium and Family Conference on June 23rd and 24th in Itasca, Illinois, USA.
GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a study in Frontiers in Microbiomes.
GC Genome’s New Study Reveals Link Between Gut Microbiome and High Blood Pressure Read More »
OSE Immunotherapeutics SA presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody Engineering & Therapeutics Europe 2023 Conference in Amsterdam, Netherlands, at the FOCIS 2023 Annual Meeting, the 4th Annual Cytokine-Based Drug Development Summit 2023 and at the 3rd Annual Tumor Myeloid-directed Therapies Summit 2023 in Boston, US.
With immunotherapy emerging as one of the most important treatment options in oncology, GE HealthCare has announced the first patient scanned in a Phase I clinical trial of a first-of-its kind fluorine-18 PET radiopharmaceutical specific for CD8, which is expressed on CD8+ T cells – a subpopulation of white blood cells which fight cancer.
Metagen Therapeutics, a company focusing on drug discovery and development based on intestinal microbiome-based therapeutics for various diseases, has completed its Series A funding in 2 rounds, raising a total of 1.7 billion yen.
Metagen Therapeutics Completes Series A Financing Raising a Total of 1.7 Billion Yen Read More »
Editas Medicine, Inc., a clinical-stage genome editing company, announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.
Editas Medicine Announces Pricing of Offering of Common Stock – June 15, 2023 Read More »
The Annual General Shareholder Meeting of Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, met in Paris on June 13, 2023, and adopted all the resolutions put to the vote.
Results of the Annual General Shareholder Meeting as of June 13, 2023 Read More »
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced the pricing of an underwritten public offering of common stock.
Bone Biologics Prices $5.0 Million Underwritten Public Offering Read More »
See inside for the top 20 biopharma companies with the most significant gaps in pay between their chief executives and median employees.
Biopharma Companies with the Biggest CEO-Employee Pay Gaps Read More »
